report
china
patient
crudefat
rate
cfr
among
infect
patient
higher
mortal
rate
among
age
year
older
among
cancer
patient
cfr
hand
cfr
italian
popul
higher
reach
attribut
older
age
distribut
differ
select
test
strategi
mainli
symptomat
patient
small
sampl
italian
patient
activ
cancer
common
comorbid
anoth
report
chines
popul
case
histori
activ
cancer
patient
higher
proport
seriou
event
occurr
defin
percentag
intens
care
admiss
invas
ventil
death
comparison
without
cancer
older
age
repres
risk
factor
seriou
event
sever
strategi
propos
author
close
monitor
cancer
patient
includ
postpon
chemotherapi
surgeri
stabl
patient
closer
surveil
strategi
elderli
patient
multipl
comorbid
howev
data
cautious
interpret
due
rel
small
sampl
size
also
histori
smoke
consid
predispos
factor
patient
increas
suscept
infect
sinc
tobacco
increas
express
angiotensinconvert
enzym
bind
receptor
addit
cancer
associ
overexpress
immunosuppress
cytokin
reduc
proinflammatori
danger
signal
enhanc
function
immunosuppress
leukocyt
popul
may
induc
blunt
immun
system
increas
possibl
infecti
complic
march
nation
health
servic
nh
publish
report
manag
cancer
patient
coronaviru
pandem
larg
proport
cancer
patient
consid
utmost
risk
infect
patient
receiv
activ
chemotherapi
radiat
therapi
hematolog
cancer
bone
marrow
transplant
well
receiv
target
therapi
protein
kinas
parp
inhibitor
immun
therapi
interestingli
patient
treat
immun
checkpoint
inhibitor
ici
consid
highli
vulner
test
posit
coronaviru
infect
sinc
introduct
therapeut
arsen
cancer
ici
revolution
treatment
sequenc
cancer
manag
monoclon
antibodi
target
immun
checkpoint
role
restor
antitumor
immun
revers
immun
escap
evas
led
signific
antitumor
activ
confirm
impact
durat
tumor
respons
prolong
overal
surviv
earn
fast
approv
across
multipl
cancer
subtyp
includ
melanoma
lung
cancer
urolog
tumor
breast
cancer
solid
tumor
importantli
agent
earn
sever
indic
monotherapi
without
associ
chemotherapeut
agent
thu
predispos
cancer
patient
differ
toler
toxic
profil
agent
led
occurr
new
spectrum
immunerel
advers
event
ira
rang
moder
sever
lifethreaten
one
side
effect
includ
wide
varieti
advers
event
endocrin
abnorm
thyroid
dysfunct
adren
insuffici
hypophys
gastrointestin
event
coliti
hepat
dermatolog
respiratori
event
interstiti
pneumon
merit
high
index
suspicion
clear
therapeut
strategi
order
prevent
irrevers
outcom
pandem
phase
coronaviru
care
monitor
cancer
patient
undergo
activ
therapi
prevent
irrevers
lifethreaten
outcom
fact
cancer
patient
receiv
cytotox
chemotherapi
high
risk
develop
infecti
complic
mainli
due
impact
myeloprolif
cell
bone
marrow
also
rapidli
divid
cell
includ
gut
mucosa
cell
lead
disrupt
protect
barrier
therefor
patient
receiv
activ
chemotherapi
often
develop
neutropenia
patient
might
develop
febril
neutropenia
also
patient
undergo
hematopoiet
stem
cell
transplant
receiv
chemotherapi
hematolog
cancer
highest
risk
develop
prolong
neutropenia
febril
neutropenia
episod
hand
data
hematolog
ira
secondari
ici
seem
comfort
occurr
uncommon
differ
form
advers
event
includ
autoimmun
thrombocytopenia
neutropenia
antibodymedi
hemolyt
anemia
thrombot
thrombocytopen
purpura
advers
event
highlight
crosstalk
humor
cellular
immun
tregmedi
selftoler
fact
ici
might
play
role
boost
pathogenspecif
immun
respons
contrast
immun
checkpoint
agonist
abatacept
impact
immun
system
may
benefici
counter
immunosuppress
microenviron
caus
immunosuppress
case
report
sever
icirel
neutropenia
mostli
secondari
agent
ipilimumab
overal
rate
grade
rate
neutropenia
remain
low
around
overal
occurr
around
incid
febril
neutropenia
small
seri
finkel
et
al
analyz
characterist
patient
immunerel
neutropenia
irn
patient
median
time
onset
irn
introduct
ici
day
incid
febril
neutropenia
ir
neutropenia
resolv
case
combin
therapeut
agent
includ
oral
intraven
steroid
granulocyt
colonystimul
factor
intraven
immunoglobulin
said
incid
sever
neutropenia
secondari
ici
rare
control
adapt
therapeut
strategi
occur
moreov
instaur
prolong
immunosuppress
agent
corticosteroid
subset
patient
ira
might
predispos
higher
risk
infect
also
close
monitor
pandem
phase
case
infect
secondari
treatment
icirel
side
effect
report
sinc
patient
treat
ici
monotherapi
combin
therapi
might
develop
ira
also
nonsolid
data
literatur
describ
viral
infect
reactiv
complic
ici
usag
regardless
develop
ira
varicella
zoster
infect
jc
viru
hepat
b
cytomegaloviru
viru
increas
risk
pandem
manag
select
anticanc
therapi
oncolog
patient
includ
ici
must
care
balanc
casebycas
scenario
potenti
increas
risk
complic
death
coronaviru
infect
data
immunosuppress
impact
ici
cancer
patient
inconclus
seem
toler
reassur
heavi
burden
hematolog
toxic
associ
chemotherapeut
agent
sinc
abl
consid
ici
treatment
highli
immunosuppress
avoid
cancer
patient
reduc
coronaviru
infect
could
depriv
patient
highli
activ
class
drug
special
consider
given
patient
treat
ira
expos
prolong
durat
immunosuppress
agent
world
preoccupi
fight
coronaviru
adapt
strategi
recommend
cancer
commun
implement
optim
manag
oncolog
patient
could
achiev
care
select
efficaci
antitumor
weaponri
lower
risk
wean
patient
immun
system
potenti
infect
realworld
data
affect
area
eagerli
need
assess
outcom
oncolog
patient
order
enhanc
therapeut
strategi
